U
ACAD icon

UBS’s Acadia Pharmaceuticals ACAD Stock Holding History

UBS’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1.12M Buy
45,048
+4,477
+11% +$105K ﹤0.01% 3478
2014
Q2 		$916K Sell
40,571
-44,106
-52% -$921K ﹤0.01% 3626
2014
Q1 		$2.06M Sell
84,677
-32,248
-28% -$816K ﹤0.01% 2755
2013
Q4 		$2.92M Sell
116,925
-96,759
-45% -$2.28M ﹤0.01% 2428
2013
Q3 		$5.87M Buy
213,684
+107,554
+101% +$2.25M 0.01% 1576
2013
Q2 		$1.93M Buy
+106,130
New +$1.46M ﹤0.01% 2579

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

UBS's ACAD Position: Q3 2014 in Review

UBS increased its Acadia Pharmaceuticals (ACAD) stake by 11% in Q3 2014, buying an estimated $105K and bringing the position to 45,048 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3478.

UBS first reported a position in ACAD in Q2 2013 and has held it in 6 quarters since. The position peaked at $5.87M in Q3 2013. 162 funds tracked by Wall St. Rank hold ACAD as of Q3 2014.

  • UBS held 45,048 shares of Acadia Pharmaceuticals worth $1.12M as of Q3 2014.
  • UBS bought 4,477 Acadia Pharmaceuticals shares in Q3 2014, an estimated $105K.
  • Acadia Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3478 holding.
  • UBS first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Acadia Pharmaceuticals position peaked at $5.87M in Q3 2013.
  • 162 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.